Added to YB: 2024-01-02
Pitch date: 2024-01-02
LIFE [bullish]
aTyr Pharma, Inc.
-49.31%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States.
Market Cap
$73.8M
Pitch Price
$1.53
Price Target
N/A
Dividend
N/A
EV/EBITDA
0.06
P/E
-0.89
EV/Sales
-22.27
Sector
Biotechnology
Category
growth
Show full summary:
$LIFE - Good signal despite low n
$LIFE: Promising P2 data in sarcoidosis despite low n; potential 1st approval in large orphan market & platform validation. Cheap valuation vs risk/reward with key P3 data in '25. Some SSc-ILD data in '24 but sarcoidosis the main shot on goal.
Read full article (1 min)